Get the Stockscreener App
0.4505
2.68%
-0.0124
Atyr Pharma Inc stock is traded at $0.4505, with a volume of 1.53M.
It is down -2.68% in the last 24 hours and down -13.28% over the past month.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
See More
Previous Close:
$0.4629
Open:
$0.4762
24h Volume:
1.53M
Relative Volume:
0.71
Market Cap:
$44.17M
Revenue:
$190.00K
Net Income/Loss:
$-70.03M
P/E Ratio:
-0.6135
EPS:
-0.7343
Net Cash Flow:
$-59.30M
1W Performance:
-5.24%
1M Performance:
-13.28%
6M Performance:
-35.93%
1Y Performance:
-91.29%
1-Day Range:
$0.4501
$0.4883
1-Week Range:
$0.44
$0.4972
52-Week Range:
$0.395
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.4505 | 44.17M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc - GuruFocus
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st
aTyr Pharma Received Notice of Noncompliance - TradingView
aTyr Pharma (NASDAQ: ATYR) wins second Nasdaq deadline to fix sub-$1 share price - Stock Titan
aTyr Pharma (ATYR) Faces Steep Decline as Shares Test Key Support ZoneJelly Roll Trade - lwvtexas.org
FMR LLC discloses 5.94M-share stake in ATYR (NASDAQ: ATYR) Amendment No.14 - Stock Titan
aTyr Pharma Inc stock (US53227K1025): shares ease after efzofitimod Phase III plan and major holder - AD HOC NEWS
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis - TipRanks
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48 - MSN
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data - TipRanks
aTyr Pharma (ATYR) refocuses efzofitimod after EFZO-FIT miss with new Phase 3 sarcoidosis trial - Stock Titan
aTyr Pharma Inc stock (US53227K1025): Insider buying and price gains draw focus - AD HOC NEWS
aTYR Pharma director Paul Schimmel buys $49,630 in common stock By Investing.com - Investing.com Australia
aTYR Pharma director Paul Schimmel buys $49,630 in common stock - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Director at aTyr Pharma (NASDAQ: ATYR) adds 100K shares - Stock Titan
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com Nigeria
aTyr Pharma (ATYR) Slips 1.22%, Approaching Key Support at $0.46Total Put Call - newsline.com
aTyr Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Some Relief Amid Pipeline DevelopmentBasic EPS Analysis - newsline.com
Why Is aTyr Stock Falling Today? - MSN
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS
ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus
ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo
ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo
aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks
Freedom Broker upgrades ATYR Pharma (ATYR) - MSN
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView
aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan
aTyr: Advancing Efzofitimod for Pulmonary Sarcoidosis - GuruFocus
aTyr Pharma Inc options imply 30.5% move in share price post-earnings - TipRanks
aTyr Pharma Reports Q1 2026 Results, Advances Efzofitimod Phase 3 for Pulmonary Sarcoidosis After FDA Meeting - Minichart
Atyr Pharma Inc Stock (ATYR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):